Atrandi Biosciences

Atrandi Biosciences, operating from Vilnius, Lithuania, is a life sciences tool company advancing high-throughput single-cell analysis. Founded in 2016 as Droplet Genomics, the company was established by pioneers in single-cell genomics with academic roots at institutions including Harvard, Columbia, and Vilnius University. The venture is co-founded by CEO Juozas Nainys, who holds a Ph.D. in biochemistry from Vilnius University and was a visiting research scholar at Columbia University, bringing over a decade of scientific experience to the firm. The company rebranded to Atrandi Biosciences in 2022, a name derived from the Lithuanian for "you discover," reflecting its mission to empower scientific research.

The firm's core business revolves around developing and commercializing droplet microfluidic technologies to overcome the limitations of conventional single-cell analysis methods, such as high costs and restricted applicability. Atrandi's key technological development is its patented Semi-Permeable Capsule (SPC) technology. This platform encapsulates individual cells in permeable compartments, allowing for multi-step molecular biology reactions and analysis on a massive scale while preserving single-cell resolution. This approach enables researchers to conduct complex experiments, like jointly profiling DNA and RNA from the same cell, which was previously challenging. The business model centers on selling hardware systems, consumables, and software to academic and commercial laboratories globally. Its product portfolio includes the Flux Microfluidic Device for single-cell isolation, the Onyx Droplet Generator for various applications, and the Styx platform for fluorescence-activated droplet sorting.

Serving a global client base of over 200 research labs, Atrandi provides tools that are crucial for fields like personalized oncology, microbial genomics, and AI-driven drug discovery. The company has secured significant funding to fuel its growth, including a €4.5 million round in 2023 and a subsequent $25 million Series A in early 2025, led by investors such as Lux Capital, Vsquared Ventures, and Practica Capital. This capital is being used to expand its U.S. presence with a new office in Boston, further develop its SPC technology, and broaden its product offerings to accelerate its global commercialization efforts.

Keywords: single-cell analysis, droplet microfluidics, semi-permeable capsule technology, life sciences tools, high-throughput screening, genomics, biotechnology, molecular biology, Juozas Nainys, single-cell multiomics, DNA sequencing, microbial genomics, lab-on-a-chip, cell biology, drug discovery, personalized medicine, Flux Microfluidic Device, Onyx Droplet Generator, Styx, Vilnius biotech